- Home
- GILD vs ANET Comparison
GILD vs ANET Comparison
Compare GILD & ANET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- ANET
- Stock Information
- Founded
- GILD 1987
- ANET 2004
- Country
- GILD United States
- ANET United States
- Employees
- GILD N/A
- ANET N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- ANET Computer Communications Equipment
- Sector
- GILD Health Care
- ANET Telecommunications
- Exchange
- GILD Nasdaq
- ANET Nasdaq
- Market Cap
- GILD 139.6B
- ANET 192.4B
- IPO Year
- GILD 1992
- ANET 2014
- Fundamental
- Price
- GILD $112.26
- ANET $142.83
- Analyst Decision
- GILD Buy
- ANET Strong Buy
- Analyst Count
- GILD 23
- ANET 15
- Target Price
- GILD $116.36
- ANET $161.33
- AVG Volume (30 Days)
- GILD 5.9M
- ANET 9.1M
- Earning Date
- GILD 11-05-2025
- ANET 11-06-2025
- Dividend Yield
- GILD 2.82%
- ANET N/A
- EPS Growth
- GILD 496.80
- ANET 31.78
- EPS
- GILD 5.01
- ANET 2.55
- Revenue
- GILD $28,863,000,000.00
- ANET $7,950,946,000.00
- Revenue This Year
- GILD $2.07
- ANET $27.59
- Revenue Next Year
- GILD $3.95
- ANET $19.17
- P/E Ratio
- GILD $22.38
- ANET $55.99
- Revenue Growth
- GILD 3.81
- ANET 25.97
- 52 Week Low
- GILD $81.83
- ANET $59.43
- 52 Week High
- GILD $121.83
- ANET $156.32
- Technical
- Relative Strength Index (RSI)
- GILD 44.36
- ANET 56.35
- Support Level
- GILD $110.15
- ANET $139.02
- Resistance Level
- GILD $114.13
- ANET $147.37
- Average True Range (ATR)
- GILD 2.21
- ANET 5.51
- MACD
- GILD -0.40
- ANET -0.49
- Stochastic Oscillator
- GILD 26.51
- ANET 48.07
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About ANET Arista Networks Inc.
Arista Networks is a networking equipment provider that primarily sells Ethernet switches and software to data centers. Its marquee product is its extensible operating system, or EOS, that runs a single image across every single one of its devices. The firm operates as one reportable segment. It has steadily gained market share since its founding in 2004, with a focus on high-speed applications. Arista counts Microsoft and Meta Platforms as its largest customers and derives roughly three quarters of its sales from North America.